Studies show BiPAP failure rates (resulting in intubation, mortality, or patient withdrawal) ranging from 20%
to 40% within the first 24–72 hours, with elevated rates in patients with severe hypoxemia or mixed
respiratory failure (e.g., ARDS or pneumonia).1 Many recommend that Hospital Respiratory/Pulmonary
Departments conduct a BiPAP Failure Root Cause Analysis (RCA) to assess the incidence of failure, identify
contributing factors, and enhance the efficacy of interventions.

​

Primary Factors Contributing to BiPAP Failure and Avoidance

​

Lung Decompensation: A comprehensive review indicates that 30-50% of NIV failures are attributed to persistent gas exchange impairment. This is often seen in conditions like acute respiratory distress syndrome (ARDS) or pneumonia, where loss of lung compliance or inadequate positive pressure contributes to ineffective gas exchange.2

​

The 30-50% figure specifically reflects cases where gas exchange could not be corrected, encompassing issues like insufficient positive pressure or failure to overcome low lung compliance, leading to decompensation and intubation.2

​

“Oxygenation impairment, as shown by a decreased ratio of PaO2 to Fi02 (P/F ratio), is one of the most well-documented risk factors and predictors of NIV failure.” “A prospective multicenter study investigating variables predictive of NIV failure in 354 patients with hypoxemic ARF reported a higher need for endotracheal intubations (ETI) in patients with ARDS (51%) and community-acquired pneumonia (CAP)(50%) than with patients with pulmonary contusion (18%) and cardiogenic pulmonary edema (CPE)(10%). In this study, most ETIs occurred due to the inability of NIV to correct gas exchange (62%)”3

A weak cough reflex leading to insufficient clearance of excessive secretions from airways is a common
cause of immediate NIV failure.3

​

​

What impact does BiPAP airway management, including oral suctioning, have on gas exchange?
Clearing airway secretions with pneumonia patients improves lung compliance—the ability of the lungs to
stretch and expand—through the following mechanisms:

1. Restoration of Alveolar Function: Secretions, such as mucus or pus, can obstruct airways and fill
alveoli, leading to consolidation or collapse of these air sacs. Clearing secretions reopens alveoli,
allowing them to participate in gas exchange and making the lungs more flexible and compliant.
2. Reduction of Airway Resistance: Accumulated secretions narrow airways, increasing resistance to
airflow. Removing these secretions widens the airways, reducing resistance and allowing easier lung
expansion, which improves compliance.
3. Improved Surfactant Effectiveness: Secretions can interfere with pulmonary surfactant, which
reduces surface tension in the alveoli. Clearing secretions helps restore surfactant function,
lowering surface tension and making the lungs more elastic and compliant.
4. Decreased Inflammation and Edema: Secretions can perpetuate local inflammation, contributing
to edema and tissue stiffness. Clearing them reduces

5. Enhanced Ventilation: By removing obstructions, clearing secretions improves ventilation to
previously blocked areas, allowing more uniform lung expansion. This reduces areas of atelectasis
(lung collapse), which can stiffen lung tissue and decrease compliance.

​

Techniques like secretion control (suctioning), chest physiotherapy, or mucolytic therapies can facilitate secretion clearance, leading to these improvements. By restoring airway patency and alveolar function, the lungs become less stiff, directly enhancing compliance and easing the work of breathing.

​

Loss of Airway: Excessive secretions, plugging and nosocomial pneumonia are major contributors, often necessitating intubation. Inadequate clearance of secretions can reduce the number of BiPAP placements or early discontinuation in fear of mucus plugging. This is a factor in approximately 10–20% of acute respiratory failure cases.4

​

“The combination of ARF and pneumonia is probably one of the strongest determinants of NIV failure(59).3 “During a hospital stay, pneumonia was more frequently observed as a complication in late failure group compared to a success group (12.9% vs 0%). The mortality rate of the late failure group was extremely high compared to the successful group in another study (68% vs 0%)”3

​

Mask Intolerance/Non-Compliance: Approximately 20-30% of BiPAP patients fail due to mask intolerance or non-compliance, accounting for 5-8% of all BiPAP patients.4

​

“...for patients with a weak cough reflex or excessive secretions, cautious secretion management during NIV use might be advisable before NIV is declared as failed.”

​

BiPAP Airway Management Strategies with ReddyPort®
ReddyPort enables clinicians the delivery of compliant and on-demand airway suctioning, oral care and dry mouth relief without removing the BiPAP mask, thus promoting efficient lung compliance and therapeutic pressures. Since the BiPAP mask remains on the patient, careful suctioning can occur without introducing lung compliance and desaturation risks.

​

ReddyPort’s Yankauer and Suctions swab appliances yield BiPAP success by:

• Preserving airway integrity with oral access for routine suction, mitigating the risk of oral secretions
and plugging known to obstruct effective gas exchange.
• ADA compliant 2 minute toothbrushing, mitigating BAP (BiPAP Acquired Pneumonia) without mask
removal or loss of positive pressure.

Delivering dry mouth relief improves patient compliance and satisfaction without mask removal or loss of
positive pressure.

​

​

Effectiveness of ReddyPort
ReddyPort is an innovative system designed to enhance airway management while preventing unintended mask removal and maintaining therapeutic pressures. Since its introduction in 2021, ReddyPort has supported over 15,000 patients and facilitated more than 60,000 oral suctioning and oral care procedures without requiring mask removal or compromising lung compliance.

​

"Implementing regular oral care in patients receiving non-invasive ventilation (NIV) is essential to clear secretions, reduce the risk of ventilator-associated pneumonia (VAP), improve patient comfort, and maintain mucosal integrity, thereby decreasing NIV failure rates."
-Chak Reddy, MD, MS.

​

​